Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes onlyHR 0.9 [0.7, 1.16]4 studies · 658 participantsLow